Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma

• Main Authors: Amrita Krishnan (Author), Ajay K Nooka (Author), Ajai Chari (Author), Alfred L Garfall (Author), Thomas G Martin (Author), Sandhya Nair (Author), Xiwu Lin (Author), Keqin Qi (Author), Anil Londhe (Author), Lixia Pei (Author), Eric Ammann (Author), Rachel Kobos (Author), Jennifer Smit (Author), Trilok Parekh (Author), Alexander Marshall (Author), Mary Slavcev (Author), Saad Z Usmani (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2023-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: We compared the effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) in triple-class exposed relapsed/refractory multiple myeloma. Materials & methods: MajesTEC- 1 eligibility criteria were applied to the RWPC cohort. Baseline covariate imbalances were ad...